01:26 PM EDT, 09/12/2024 (MT Newswires) -- Sernova ( SEOVF ) on Thursday announced the presentation of new positive interim data from the ongoing Phase I/II clinical trial evaluating the Sernova Cell Pouch Transplant System containing donor islets in people living with type 1 diabetes (T1D).

The company, which is developing regenerative medicine cell therapies to treat chronic diseases, said six patients in Cohort A of the trial achieved sustained insulin independence after combined islet transplantation into the Sernova Cell Pouch and into the portal vein (intraportally.)

The first patient to be treated experienced insulin independence for more than four years accompanied by blood sugar levels in the non-diabetic range. More than five years after the first islet transplant, the patient's Cell Pouches were removed because immune suppression had to be stopped when they developed other, non-diabetic health issues, Senova said.

"We look forward to completing Cohort B in the near term and, based on positive data generated thus far, initiating Cohort C of our ongoing trial later this year with an optimized immune suppression regimen," said CEO Jonathan Rigby.

The data was presented during an oral session at the European Association for the Study of Diabetes Annual Meeting in Madrid, Spain.

Senova was last seen down $0.03 to $0.27, on the Toronto Stock Exchange.

Price: 0.27, Change: -0.03, Percent Change: -8.47